No description
-
2016 (v1)PublicationUploaded on: April 14, 2023
-
2021 (v1)Publication
: Identification of novel vulnerabilities in the context of therapeutic resistance is emerging as key challenge for cancer treatment. Recent studies have detected pervasive aberrant splicing in cancer cells, supporting its targeting for novel therapeutic strategies. Here, we evaluated the expression of several spliceosome machinery components...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy for treating a variety of human diseases including cancer. Here, we show that GPER1 is significantly upregulated in tumor cells from different cohorts of Waldenstrom Macroglobulinemia (WM) patients compared to normal B cells. Using the clinically...
Uploaded on: February 4, 2024 -
2022 (v1)Publication
Identification of novel vulnerabilities in the context of therapeutic resistance is emerging as a key challenge for cancer treatment. Recent studies have detected pervasive aberrant splicing in cancer cells, supporting its targeting for novel therapeutic strategies. Here, we evaluated the expression of several spliceosome machinery components...
Uploaded on: February 11, 2024 -
2017 (v1)Publication
Dysregulated oncogenic serine/threonine kinases play a pathological role in diverse forms of malignancies, including multiple myeloma (MM), and thus represent potential therapeutic targets. Here, we evaluated the biological and functional role of p21-activated kinase 4 (PAK4) and its potential as a new target in MM for clinical applications....
Uploaded on: March 27, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023